Head and neck squamous cell carcinoma (HNSCC) represents the eighth most common malignancy worldwide. Standard of care treatments include surgery, radiation and chemotherapy. Additionally, the anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab is commonly used. Despite clinical success with these therapies, HNSCC remains a difficult to treat malignancy. Thus, identification of molecular targets is critical. In the current study, the receptor tyrosine kinase AXL was overexpressed and significantly associated with higher pathologic grade, distant metastases, and shorter relapse free survival in HNSCC patients. Based on these findings, AXL was evaluated as a molecular target in HNSCC models using the clinically relevant tyrosine kinase inhibitor R428, where AXL targeting enhanced the efficacy of platinum chemotherapy, cetuximab, and radiation. Importantly, AXL was Experimental Design: In the current study, the receptor tyrosine kinase AXL was investigated as a molecular target in HNSCC using established cell lines, HNSCC patient derived xenografts (PDXs), and human tumors. HNSCC dependency on AXL was evaluated with both anti-AXL siRNAs and the small molecule AXL inhibitor R428. Furthermore, AXL inhibition was evaluated with standard of care treatment regimes used in HNSCC.
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Statement of Clinical Impact
Head and neck squamous cell carcinoma (HNSCC) represents the eighth most common malignancy worldwide. Standard of care treatments include surgery, radiation and chemotherapy. Additionally, the anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab is commonly used. Despite clinical success with these therapies, HNSCC remains a difficult to treat malignancy. Thus, identification of molecular targets is critical. In the current study, the receptor tyrosine kinase AXL was overexpressed and significantly associated with higher pathologic grade, distant metastases, and shorter relapse free survival in HNSCC patients. Based on these findings, AXL was evaluated as a molecular target in HNSCC models using the clinically relevant tyrosine kinase inhibitor R428, where AXL targeting enhanced the efficacy of platinum chemotherapy, cetuximab, and radiation. Importantly, AXL was overexpressed and hyperactivated in radiation resistant in vivo HNSCC models. Collectively, these studies provide rationale for the clinical evaluation of anti-AXL therapeutics for the treatment of patients with HNSCC. 
Introduction
With more than 600,000 new cases diagnosed worldwide each year, head and neck squamous cell carcinoma (HNSCC) represents the eighth most common malignancy (1) . HNSCC arises from epithelial cells that comprise the mucosal surfaces of the lips, oral cavity, larynx, pharynx, and nasal passages. Classically, these malignancies were highly associated with alcohol and tobacco abuse, but over the past decade it has been determined that human papillomavirus (HPV) is causally associated with a subset of HNSCCs (2) .
Approximately 60% of patients with HNSCC present with locoregionally advanced disease at the time of diagnosis. In order to achieve the greatest chance for cure, these patients are typically treated with a multimodality approach of systemic chemotherapy, radiation, and surgery (3) (4) (5) . Advances in molecular targeting of HNSCC have found that cetuximab, an antiepidermal growth factor receptor (EGFR) monoclonal antibody, can benefit patients when combined with platinum chemotherapy or radiation (6) (7) (8) . While advances in these treatment modalities have improved patient outcomes, many patients still develop recurrent tumors and distant metastases. Upon relapse, patient survival remains poor. In this manner, the identification of new therapeutic targets is critical.
The receptor tyrosine kinase AXL has now been implicated in the development and progression of many malignancies, including lung (9) (10) (11) (12) (13) (14) , breast (12, (15) (16) (17) (18) (19) , ovarian (20) , colon 5 that AXL can mediate resistance to anti-EGFR inhibitors, further unveiling a role for AXL in cancer progression (9, 11, 13, 22, 30, 31 ). In the current study, we sought to determine if AXL is a functional molecular target in HNSCC, and if targeting AXL could enhance the efficacy of standard treatments used to treat HNSCC patients.
Research. Immunoblot analysis. Whole-cell lysis, immunoprecipitation and western blot analysis was performed as previously described (30) . Enhanced chemiluminescence (ECL) detection system was used to visualize proteins.
Wound healing assay. Cells were plated in 6-well culture plates. Upon 80-90% confluence, the cell layer was scratched with a p-200 pipette tip (3 scratches per well, 2-3 wells per treatment).
The cells were then cultivated in complete medium with/without indicated doses of R428.
Alternatively, cells were transfected with siAXL or siNT for 24 hours prior to wound exposure.
Photographs of the wound adjacent to reference lines were taken using an Olympus IX51 microscope (10×) at indicated time points. CellSens Standard 1.9 software (Olympus) was used to digitally measure wound closure; wound closure at each time point was normalized to the averaged scratch width measured at time 0.
Research. γ-H2AX fluorescent assay. Cells were plated in 96-well dishes and pre-treated with vehicle or R428 (1uM). A novel high-throughput irradiator utilizing a 50 kVp x-ray beam spectrum was used to deliver 4 gray (Gy) as previously described (33, 34) . Cells were fixed in 4% paraformaldehyde 4 hours later, permeabilized in 90% methanol, blocked, and incubated with γ-H2AX primary antibody (1:500) overnight. Cells were washed and incubated with FITC conjugated secondary antibody (1:1000) (Santa Cruz Biotechnology). γ-H2AX fluorescence per cell was evaluated via a SpectraMax i3 plate reader with MiniMax 300 imaging cytometer using SoftMax Pro v6.4 software (Molecular Devices, Sunnyvale, CA, USA). All γ-H2AX fluorescent values were averaged and then normalized to averaged values from vehicle treated cells.
Cell line xenografts, patient derived xenografts (PDXs), and radiation response. Cell line xenografts and PDXs were established as previously described (30, 35, 36 Collectively, these data indicated that HNSCC cell lines expressed AXL and were dependent on this receptor for proliferation.
To expand these findings, a 22 PDX TMA was stained for AXL via immunohistochemistry (IHC) using a previously validated anti-AXL antibody (30) . This TMA 
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AXL inhibition effectively reduces HNSCC cell growth, migration, and invasion. Since several HNSCC cell lines were sensitive to AXL knockdown by siRNA, we hypothesized that these cells would also be sensitive to the AXL tyrosine kinase inhibitor R428. R428 specificity for AXL has been previously evaluated (15) , and this agent has now undergone successful phase Ia clinical evaluation (38) . HNSCC cells were treated with increasing doses of R428 (0.001 uM - Table 3A and 3B). Additionally, siRNA targeting AXL synergized with cisplatin, providing further evidence for the specificity of R428 for AXL inhibition (Supplemental Figure 3A) . Collectively, these results demonstrate that AXL inhibition enhances chemotherapy sensitivity in HNSCC cells.
Since AXL expression has been shown to mediate cetuximab resistance (30), we hypothesized that AXL inhibition may improve the efficacy of cetuximab therapy in HNSCC.
Therefore, several HNSCC cell lines were treated with vehicle, R428 (1.0 uM), cetuximab (100 nM), or the combination, and cellular proliferation was measured 72 hours later ( Figure 3B ).
Three cell lines (SCC4, SCC6, and SCC104) were resistant to cetuximab, while HN4 was sensitive to cetuximab monotherapy. Importantly, when treated with both R428 and cetuximab, all cell lines demonstrated significant reductions in cellular proliferation as compared to cells treated with R428 only. The resulting effect of both drugs was determined to be synergistic in all cell lines except for HN4, where an additive effect was observed (Supplemental Table 3C ).
Additional siRNA studies confirmed specificity of R428 for AXL inhibition, as AXL knockdown synergized with cetuximab in all cell lines tested (Supplemental Figure 3B) 
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dose response proliferation assays demonstrated HN4-AXL cells were statistically more resistant to increasing doses of cetuximab as compared to HN4-Vector cells (Figure 3C ). Immunoblot analysis of HN4-AXL cells indicated increased activation of proteins previously reported to play a role in cetuximab resistance, including increased phosphorylation of EGFR on tyrosine 1101 and src family kinases (SFKs) (42) (43) (44) . Additionally, HN4-AXL cells had decreased levels of Ecadherin and increased levels of vimentin, two hallmarks of cells that have undergone epithelialto-mesenchymal transition (EMT). Taken together, these studies support a role for AXL in cetuximab resistance, and suggest that AXL inhibition can enhance cetuximab sensitivity in HNSCC cells.
Targeting AXL can enhance the efficacy of radiation therapy in HNSCC. It is well established that several RTKs play a role in modulating DNA repair pathways and response to radiation therapy (45, 46) . However, the role of AXL in radiation response has never been investigated. A previous report has indicated differential radiation responses for several HNSCC cell lines that express AXL (Figure 1A) , including SCC1, SCC47, and SCC147T (35) . We thus examined if AXL inhibition could augment the sensitivity of these cell lines to radiotherapy.
Using a high-throughput x-ray radiation system that delivers the same absorbed dose of ionizing radiation to cells plated in a 96-well format (development and characterization (33) Table 3C ). R428 pre-treated SCC2 cells did not demonstrate a reduction in survival as compared to cells treated with radiation only. Finally, AXL knockdown with siRNA prior to radiation exposure resulted in reduced cellular viability, further supporting the AXL specific radiosensitizing effects of R428 (Supplemental Figure 3C) .
To investigate the potential molecular mechanisms underlying this enhanced radiation response, the activation of DNA-protein kinase (DNA-PK) and AKT were examined post R428 and radiation therapy ( Figure 4C) . DNA-PK is largely responsible for mediating DNA DSB repair through nonhomologous end joining, and thus, when activated can lead to radiation resistance (47) . AKT is an intracellular serine/threonine kinase that directly interacts with DNA- (Figure 4D, middle) . Additionally, HN4-AXL cells expressed increased levels of phosphorylated DNA-PK and AKT post irradiation (Figure 4D, right) .
Collectively, these studies support a putative role for AXL in the regulation of DNA repair and resistance to radiation.
AXL is overexpressed in radiation resistant cell line and patient derived xenografts.
To expand these findings, the HNSCC cell lines SCC2, SCC22B, SCC90, SCC1, SCC47, and SCC147T were injected into both dorsal flanks of athymic nude mice (n=24 mice per cell line). experimentation indicated that SCC2, SCC22B, and SCC90 cell line xenografts were sensitive to radiation, while SCC1, SCC47, and SCC147T were resistant ( Figure 5) . Tumors harvested from mice in the control groups were evaluated for AXL expression and activation by IHC and staining intensity was scored as described in Figure 1B . On average, the radiosensitive tumors expressed low levels of both AXL and pAXL-Y779 (1+ to 2+), with SCC2 and SCC90 having the lowest levels of staining (consistent with AXL expression levels detected in Figure 1A) . The 
Discussion
The current study identifies AXL to be highly expressed and associated with worse clinical outcome in HNSCC. Elevated AXL expression has been identified as a poor prognostic factor for shorter relapse free survival or overall survival in colon cancer (21) , pancreatic cancer (25) , and osteosarcoma (26) . Additionally, AXL expression was prognostic for increased lymph node involvement and/or clinical stage in lung adenocarcinoma (14) , ovarian cancer (20) , and breast cancer (19) . Interestingly, male gender was associated with high AXL expression in the current study, which is an association that has not been reported in other cancers. Several preclinical studies have highlighted the importance of AXL in regulating the metastatic potential of cancer cells (12, 14, 15, 17-19, 23, 24, 27) , which is in agreement with the current findings (Figures 2B and 2C) . HNSCC cell proliferation was also decreased upon AXL knockdown or kinase inhibition (Figures 1A and 2A) , which is contrary to studies in ovarian cancer where only metastatic spread was abrogated post AXL knockdown (20) . In models of breast and lung cancer, cell proliferation was decreased upon AXL inhibition as well, which corresponded to increased chemosensitivity (10, 18, 49) . Taken together, targeting AXL may inhibit both proliferation and motility pathways in HNSCC.
AXL has been reported to play a role in resistance to chemotherapy and anti-EGFR therapies in non small cell lung cancer (NSCLC) (9-11, 49), triple-negative breast cancer (TNBC) (13, 16, 49) and HNSCC (22) . In this study, several HNSCC cell lines that were intrinsically resistant to cetuximab were sensitized upon transfection with siAXL or treatment with R428 ( Figure 3B and Supplemental Figure 3B) . Additionally, AXL inhibition enhanced the anti-proliferative effect of cetuximab in a cetuximab sensitive cell line (HN4) (Figure 3B ).
These data indicate that dual targeting both AXL and EGFR may provide beneficial anti-tumor has been implicated in mediating the nuclear translocation of EGFR, a reported mechanism of cetuximab resistance (42, 44 ). In the current study, HN4 cells stably overexpressing AXL had an increased EMT signature, SFK activity and pEGFR-Y1101, all of which corresponded to increased cetuximab resistance ( Figure 3C ). This data is supported by studies identifying a similar AXL regulated EMT signature in erlotinib resistant HNSCC (22) , TNBC (16) , and NSCLC cell models (9, 49) .
One of the most profound findings of the current study was the identification of AXL overexpression and hyperactivation in radiation resistant HNSCC cell line xenografts and PDXs (Figures 5 and 6) . The correlation between AXL expression and activity in the radiation resistant tumors implies an inherit role for AXL in radiation resistance. This is supported in Figure 4 , where AXL inhibition increased γ-H2AX foci and enhanced the sensitivity of HNSCC cells to radiation (Figures 4A and 4B) . AXL was further found to regulate the DNA repair pathway via AKT and DNA-PK activity (Figures 4C and 4D) . Since AKT and DNA-PK mediate DNA repair, their increased activity has been indicative of radioresistant cancer cells (47, 48) ; thus, targeting AXL may have radiosensitizing effects in HNSCC. Collectively, these studies are the first to identify AXL as a mediator of radiation response in HNSCC.
HPV infection has been shown to play a causal role in the development of a subset of HNSCCs (2) . Importantly, patients with HPV-positive HNSCC demonstrate significantly improved survival outcome with standard of care treatments (37, 51 
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underlying the improved outcome of the HPV-positive population has been attributed to their increased sensitivity to radiation therapy (37, 52) . However, there are several important molecular differences driving oncogenesis in HPV-positive versus HPV-negative HNSCCs that likely underlie the differential treatment response observed (53, 54) . In the current study, among the 63 patient cohort, AXL expression was not associated with HPV-positivity (as determined by p16 IHC). Although no correlation was determined, it is important to note that approximately 27% of the patients in this cohort had oropharyngeal cancer (anatomic area including the tonsils, base of tongue, soft palate and lateral/posterior pharyngeal walls). Considering the oropharynx represents the site with the greatest proportion of HPV-associated cancers that are accurately defined by p16 expression (55) , it would be important in the future to specifically evaluate the relationship between HPV status and AXL staining in patients with oropharyngeal cancers and compare the results to patients with non-oropharyngeal malignancies. In this manner, further research is required to determine whether there is a significant relationship between HPV status and AXL expression/function in HNSCC.
Several anti-AXL therapeutics are currently being evaluated for movement into clinical trials. R428, licensed as BGB324, has now undergone successful Phase Ia clinical evaluation in healthy volunteers, where it was deemed safe and well tolerated (38) . While R428 is greater than 100 times more selective for AXL than several other tyrosine kinases (such as the insulin receptor, EGFR, and HER2), we cannot rule out the possibility that the anti-tumor responses observed in the current study were solely due to AXL inhibition (15) . However, the use of both AXL siRNAs and the AXL negative cell line, SCC2, throughout this study supports the specificity for AXL inhibition by R428. Several neutralizing anti-AXL monoclonal antibodies have also been designed, including YW327.6S2 and MAb173 (13, 27, 30) , however, these 
